Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Pipeline Review, H1 2018’, provides in depth analysis on Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology under development targeting Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

– The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects

– The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AC Immune SA

AFFiRiS AG

BioArctic AB

Biogen Inc

Denali Therapeutics Inc

Evotec AG

Fulcrum Therapeutics Inc

Genmab A/S

ICB International Inc

MedImmune LLC

Neuropore Therapies Inc

nLife Therapeutics SL

Priavoid GmbH

ProMIS Neurosciences Inc

Prothena Corp Plc

QR Pharma Inc

reMYND NV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Overview

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Companies Involved in Therapeutics Development

AC Immune SA

AFFiRiS AG

BioArctic AB

Biogen Inc

Denali Therapeutics Inc

Evotec AG

Fulcrum Therapeutics Inc

Genmab A/S

ICB International Inc

MedImmune LLC

Neuropore Therapies Inc

nLife Therapeutics SL

Priavoid GmbH

ProMIS Neurosciences Inc

Prothena Corp Plc

QR Pharma Inc

reMYND NV

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drug Profiles

ABL-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit Alpha-Synuclein for Glaucoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1947D Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1948D Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1949D Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950D Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950R Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-0805 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-054 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLR-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Parkinson’s Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-82422 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-1341 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLFPD-1233 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-088 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-189 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT100-18A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-04 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Posiphen Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRX-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

quinpramine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReS-9S Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson’s Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trehalose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Dormant Products

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Product Development Milestones

Featured News & Press Releases

Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy

Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT088 at Society for Neuroscience Annual Meeting

Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT189 at Society for Neuroscience Annual Meeting

Oct 13, 2017: BioArctic's Patent for its Product Candidate Antibody BAN0805, for Parkinson's Disease, is Now Granted in Europe

Jul 18, 2017: Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer’s Association International Conference (AAIC) 2017

Jul 17, 2017: Proclara Biosciences Announces Pipeline Progress

Jul 17, 2017: Proclara Biosciences Provides Update on NPT189

Jul 11, 2017: QR Pharma Presents New Data on Posiphen in Down Syndrome at the Alzheimer's Disease International Conference

Jul 05, 2017: Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease

Jun 08, 2017: Anti-Alpha-Synuclein Antibody is a Potential Disease-Modifying Treatment for Parkinson’s Disease

Jun 07, 2017: AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE PD03A, Confirming Immunogenicity and Safety Profile in Parkinson's Disease Patients

May 15, 2017: Enterin's RASMET Study Enrolls First Patient With Parkinson's Disease

Apr 02, 2017: Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease

Mar 28, 2017: Biogen to Present Data on BIIB054 at the 13th International Conference on Alzheimer's and Parkinson's Diseases

Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AC Immune SA, H1 2018

Pipeline by AFFiRiS AG, H1 2018

Pipeline by BioArctic AB, H1 2018

Pipeline by Biogen Inc, H1 2018

Pipeline by Denali Therapeutics Inc, H1 2018

Pipeline by Evotec AG, H1 2018

Pipeline by Fulcrum Therapeutics Inc, H1 2018

Pipeline by Genmab A/S, H1 2018

Pipeline by ICB International Inc, H1 2018

Pipeline by MedImmune LLC, H1 2018

Pipeline by Neuropore Therapies Inc, H1 2018

Pipeline by nLife Therapeutics SL, H1 2018

Pipeline by Priavoid GmbH, H1 2018

Pipeline by ProMIS Neurosciences Inc, H1 2018

Pipeline by Prothena Corp Plc, H1 2018

Pipeline by QR Pharma Inc, H1 2018

Pipeline by reMYND NV, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports